Authors:
Address: Centro Nacional para la Salud de la Infancia y la Adolescencia, Ministry of Health, Mexico, D.F., Mexico.
Journal:

Publication:

abstract

BACKGROUND AND AIMS:

In Mexico from December 2009 to June 2010, 45,490,501 doses of the vaccine against the influenza virus were administered; 27,048,330 of those corresponded to influenza A (H1N1) and 18,442,171 to seasonal influenza. Therefore, the assessment of Events temporarily associated with vaccination (ETAV) is mandatory.

METHODS:

The database corresponding to the ETAV associated with influenza (A [H1N1] and seasonal) immunization reported between December 2009 and June 2010 was analyzed. Patients who displayed at least one ETAV with one of the following schedules were included: A) influenza A (H1N1) vaccine, B) seasonal influenza vaccine, C) influenza A (H1N1) vaccine and seasonal influenza vaccine.

RESULTS:

A total of 597 ETAVs were reported. The 20- to 49-year-old age group was the most affected one (52.9%). The ETAV notification rate for influenza A (H1N1) vaccination was 1.41/100,000 applied doses vs. 0.74/100,000 applied doses corresponding to the seasonal influenza vaccination. Fifty seven events were considered serious (14 corresponded to Guillain-Barré syndrome) and these were considered coincidental unrelated events.

CONCLUSIONS:

There is no evidence of an increased rate of Guillain-Barré Syndrome with respect to the cases expected in the general population.

Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved.

Related Articles
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
Lancet. 2010
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
Vajo Z, Tamas F, Sinka L, Jankovics I. Lancet. 2010 Jan 2; 375(9708):49-55. Epub 2009 Dec 15.
Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series.
Vaccine. 2011
Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series.
Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Vaccine. 2011 Oct 19; 29(45):7878-82. Epub 2011 Aug 27.
Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.
MMWR Morb Mortal Wkly Rep. 2010
Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 Jun 4; 59(21):657-61.
Review Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis.
Influenza Other Respi Viruses....
Review Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis.
Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Influenza Other Respi Viruses. 2011 Sep; 5(5):299-305. Epub 2011 Mar 21.
Review Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.
Pediatrics. 2011
Review Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.
Salmon DA, Akhtar A, Mergler MJ, Vannice KS, Izurieta H, Ball R, Lee GM, Vellozzi C, Garman P, Cunningham F, et al. Pediatrics. 2011 May; 127 Suppl 1:S78-86. Epub 2011 Apr 18.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster